Use of Biologic Therapies With Different Mechanisms of Action (MOA) in the First-line (1L) Treatment of Crohn's Disease (CD) in the US

被引：0
作者：
Huang, Zhongwen [1 ]
Ba, Yi [1 ]
Kamble, Pravin [1 ]
Wang, Song [1 ]
机构：
[1] Takeda, Cambridge, MA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S917
引用
收藏
页码：S433 / S433
页数：1
相关论文
共 50 条
[1]   Use of biologic therapies with different mechanisms of action (MOA) in the first-line (1L) treatment of Crohn's Disease (CD) in the US [J].
Huang, Z. ;
Ba, Y. ;
Kamble, P. ;
Wang, S. .
JOURNAL OF CROHNS & COLITIS, 2021, 15 :S084-S084
[2]   First-Line Treatment for Children and Adolescents With Crohn's Disease [J].
Leiz, Maren ;
Moon, Kilson ;
Tischler, Luisa ;
de Laffolie, Jan ;
van den Berg, Neeltje .
DEUTSCHES ARZTEBLATT INTERNATIONAL, 2023, 120 (14) :251-252
[3]   The Impact of Treatment Switch Among Prevalent Patients With Crohn's Disease Treated With a First-Line Biologic: A US Retrospective Claims Database Study [J].
Gagnon-Sanschagrin, Patrick ;
Sanon, Myrlene ;
Davidson, Mikhail ;
Guerin, Annie ;
Willey, Cynthia ;
Kachroo, Sumesh ;
Hoops, Timothy ;
Naessens, Dominik ;
Cloutier, Martin .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10) :S592-S592
[4]   Different rate of transmural remission between first and second line of biologic treatment in Crohn's disease [J].
De Sire, R. ;
Rispo, A. ;
Caiazzo, A. ;
Testa, A. ;
Nardone, O. M. ;
Guarino, A. D. ;
Olmo, O. ;
Calabrese, G. ;
Fierro, G. ;
Toro, B. ;
Cantisani, N. M. ;
Ferrante, M. ;
La Mantia, A. ;
D'Alessandro, E. ;
Castiglione, F. .
JOURNAL OF CROHNS & COLITIS, 2023, 17 :520-520
[5]   The economic impact of suboptimal treatment and treatment switch among patients with Crohn's disease treated with a first-line biologic - A US retrospective claims database study [J].
Gagnon-Sanschagrin, Patrick ;
Sanon, Myrlene ;
Davidson, Mikhail ;
Willey, Cynthia ;
Kachroo, Sumesh ;
Hoops, Timothy ;
Naessens, Dominik ;
Guerin, Annie ;
Cloutier, Martin .
JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) :931-940
[6]   Real-world safety of first-line (1L) therapies for locally advanced or metastatic urothelial cancer (la/mUC) in the US. [J].
Nizam, Amanda ;
Kearney, Mairead ;
Morris, Valerie A. ;
Mahmoudpour, Seyed Hamidreza ;
Lobo, Carroline ;
Hoffman, Jason ;
Iliev, Ilian ;
Yerram, Prakirthi ;
Guinter, Mark .
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
[7]   Patterns and predictors of first-line (1L) taxane use in US patients with metastatic triple-negative breast cancer (mTNBC) [J].
O'Shaughnessy, J. ;
Emens, L. A. ;
Chui, S. ;
Russell, K. ;
Lin, S. -W. ;
Avile, C. Flores ;
Luhn, P. ;
Schneeweiss, A. .
ANNALS OF ONCOLOGY, 2019, 30 :131-131
[8]   Adalimumab as first-line anti-TNF treatment in pediatric Crohn's disease [J].
Martin-de-Carpi, J. ;
Navas-Lopez, V. M. ;
Navalon-Rubio, M. ;
Llerena-Santa-Cruz, E. ;
Gil-Ortega, D. ;
Varea-Calderon, V. ;
Sierra-Salinas, C. .
JOURNAL OF CROHNS & COLITIS, 2014, 8 :S309-S309
[9]   Adalimumab As First-Line Anti-TNF Treatment in Pediatric Crohn's Disease [J].
Martin-de-Carpi, Javier ;
Navas-Lopez, Victor ;
Navalon-Rubio, Maria ;
Llerena-Santa-Cruz, Enrique ;
Ortega, David Gil ;
Varea-Calderon, Vicente ;
Sierra-Salinas, Carlos .
GASTROENTEROLOGY, 2014, 146 (05) :S780-S780
[10]   Adalimumab as first-line anti-TNF treatment in pediatric Crohn's disease [J].
Martin-de-Carpi, J. ;
Navas-Lopez, V. M. ;
Navalon-Rubio, M. ;
Llerena-Santa-Cruz, E. ;
Gil-Ortega, D. ;
Varea-Calderon, V. ;
Sierra-Salinas, C. .
JOURNAL OF CROHNS & COLITIS, 2014, 8 :S427-S427
12345